| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
WAY-604116 has been reported to target multiple enzymes. It is described as an 11-β-hydroxysteroid dehydrogenase inhibitor, a sphingosine kinase inhibitor, and a potent aromatase inhibitor with an IC50 of 1.5 μM. Aromatase is the enzyme responsible for the conversion of androgens to estrogens, and its inhibition is relevant to hormone-dependent cancers. Sphingosine kinase is involved in sphingolipid metabolism and cell signaling.
|
|---|---|
| ln Vitro |
WAY-604116 is a potent aromatase inhibitor with an IC50 of 1.5 μM. It has also been described as a sphingosine kinase inhibitor and an 11-β-hydroxysteroid dehydrogenase inhibitor. The compound's multi-target activity makes it a valuable tool for studying steroid metabolism, hormone signaling, and cancer biology. Specific potency values for other targets have not been extensively reported.
|
| ln Vivo |
In vivo activity of WAY-604116 has not been extensively reported in the available literature. As an aromatase inhibitor, the compound would be expected to reduce estrogen production in vivo, which could have applications in hormone-dependent cancer research. As a sphingosine kinase inhibitor, it may modulate sphingolipid signaling. Further in vivo studies would be required to evaluate its pharmacokinetics and efficacy.
|
| Enzyme Assay |
Aromatase activity is measured using radiometric or fluorescent assays. The enzyme is incubated with androstenedione substrate and NADPH in the presence of WAY-604116 at varying concentrations. Aromatase converts androstenedione to estrone, which is measured by detecting the release of tritiated water or by fluorescence. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular activity of WAY-604116 is evaluated in aromatase-expressing cells or cancer cell lines. Cells are treated with varying concentrations of the compound, and aromatase activity is measured by assessing estrogen production. Cell proliferation assays are used to evaluate the compound's effects on hormone-dependent cancer cell growth. Sphingosine kinase activity may also be assessed in relevant cell systems.
|
| Animal Protocol |
In vivo evaluation of WAY-604116 would typically involve animal models of hormone-dependent cancers or metabolic disorders. Animals would be administered the compound orally or intraperitoneally at various doses. Tumor growth would be monitored, and hormone levels (estrogen, cortisol) would be measured in plasma and tissues. Pharmacodynamic endpoints would include assessment of target inhibition. Such studies have not been extensively reported.
|
| ADME/Pharmacokinetics |
WAY-604116 has a molecular formula of C17H22N2O and a molecular weight of 270.37. It is soluble in DMSO (10 mM). The compound is stored as powder at -20°C for up to 3 years. Its chemical name is N-[(pyridin-4-yl)methyl]adamantane-1-carboxamide. The compound has physicochemical properties suitable for research applications in steroid metabolism and cancer biology.
|
| Toxicity/Toxicokinetics |
Toxicological data for WAY-604116 are limited, as the compound is for research use only. It is not intended for human or therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. Comprehensive toxicology profiling would be required for clinical development.
|
| References | |
| Additional Infomation |
WAY-604116 is a multi-target inhibitor with activity against aromatase (IC50 = 1.5 μM), sphingosine kinase, and 11-β-hydroxysteroid dehydrogenase. It is also known as Aromatase-IN-2. The compound is used in research on steroid metabolism, hormone-dependent cancers, and sphingolipid signaling. Its ability to inhibit aromatase makes it relevant to breast cancer research, while its sphingosine kinase inhibition activity is relevant to studies of cell signaling and cancer biology. WAY-604116 is a valuable tool for studying these diverse biological pathways.
|
| Molecular Formula |
C17H22N2O
|
|---|---|
| Molecular Weight |
270.369
|
| Exact Mass |
270.17
|
| Elemental Analysis |
C, 75.52; H, 8.20; N, 10.36; O, 5.92
|
| CAS # |
121768-39-6
|
| PubChem CID |
2998104
|
| Appearance |
White to off-white to be determined
|
| LogP |
2.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
345
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C2CC3CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4
|
| InChi Key |
GYWQBPYNAGLBSC-MSNLLQCJSA-N
|
| InChi Code |
InChI=1S/C17H22N2O/c20-16(19-11-12-1-3-18-4-2-12)17-8-13-5-14(9-17)7-15(6-13)10-17/h1-4,13-15H,5-11H2,(H,19,20)/t13-,14+,15-,17?
|
| Chemical Name |
(3r,5r,7r)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide
|
| Synonyms |
WAY-604116; WAY 604116; WAY604116;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~369.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.25 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6986 mL | 18.4932 mL | 36.9864 mL | |
| 5 mM | 0.7397 mL | 3.6986 mL | 7.3973 mL | |
| 10 mM | 0.3699 mL | 1.8493 mL | 3.6986 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
